Cubist Systematic Strategies, LLC Neu Base Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $562 - $1,323	-686 Reduced 27.17%	1,839 $2,000
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $4,777 - $11,186	-3,792 Reduced 60.03%	2,525 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.6 - $4.18 $4,659 - $7,490	1,792 Added 39.6%	6,317 $18,000
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $7,543 - $10,981	-2,307 Reduced 33.77%	4,525 $16,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $31,632 - $50,146	6,832 New	6,832 $33,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.